Treace Medical Concepts (TMCI) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic growth and market positioning

• Achieved strong U.S. revenue growth and improved adjusted EBITDA, driven by expanding bunion-focused product lines and a differentiated technology strategy.

• Lapiplasty 3D Bunion Correction Procedure established as a market leader, with over 3,100 surgeon users and the largest dollar share in the U.S. bunion market.

• Addressable U.S. bunion market estimated at over $5 billion, with one in four adults affected and over a million symptomatic surgical candidates annually.

• Only 7% of the bunion market penetrated, presenting significant growth opportunities with new targeted solutions.

• Surgeon customer base grew at a 26% CAGR over five years, reaching over 3,100 active surgeons in 2024.

Product innovation and portfolio expansion

• Introduced new minimally invasive (MIS) solutions: Nanoplasty and Percuplasty, targeting the fast-growing osteotomy segment and expanding into the arthritic toe market with SpeedMTP.

• Lapiplasty system now offers a Micro-Lapiplasty option with a 2-cm incision, and Adductoplasty addresses midfoot deformities in up to 30% of bunion patients.

• SpeedPlate fixation technology rapidly adopted, now comprising over 50% of fixation kit sales and supporting premium pricing.

• IntelliGuide PSI platform enables personalized, preoperative planning and patient-specific cutting guides, with expanded access for Lapiplasty and Adductoplasty.

• Five new products and technologies will add about 80 SKUs, supporting capital-efficient growth.

Clinical evidence and reimbursement

• ALIGN3D clinical study shows sustained improvements in pain, correction, and patient-reported outcomes for Lapiplasty.

• CMS increased reimbursement rates for Lapiplasty procedures by 89% in hospital outpatient and 100% in ASC settings, effective January 2024.

• Commitment to ongoing clinical studies for new MIS procedures to support adoption and differentiation.